newsfilter
← Latest News
GlobeNewswire·

Cara Therapeutics Reports Third Quarter 2022 Financial Results

– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection – – Strong demand for KORSUVA injection driven by large dialysis organizations with ~180,000 vials